Welcome to our dedicated page for Tevogen Bio news (Ticker: TVGNW), a resource for investors and traders seeking the latest updates and insights on Tevogen Bio stock.
Tevogen Bio Holdings Inc. (Nasdaq: TVGN) is a clinical-stage biotechnology company focused on precision T cell therapies and AI-enabled drug development, and its news flow reflects this dual emphasis on science and capital-efficient execution. Company announcements highlight progress across its ExacTcell™ platform, the Tevogen Bio therapeutic pipeline, and the Tevogen.AI analytics division, as well as financial and corporate developments disclosed through SEC filings.
Readers of the Tevogen news page can expect updates on clinical and scientific milestones, such as expanded HLA coverage for its investigational T cell therapy TVGN 489, completion of target identification for additional HLA restrictions, and preclinical work in areas including EBV-associated lymphomas, chronic hepatitis B, and HPV-related cancers. The company also reports on recognition from industry and regional publications, intellectual property developments, and the evolution of its AI capabilities, including its PredicTcell™ model.
Tevogen’s news also covers financial and operational disclosures, including commentary around quarterly reports on Form 10-Q, non-GAAP metrics used by management, and statements on capital efficiency and cash burn. In addition, the company issues releases on corporate actions such as at-the-market equity programs and personal contributions by its founder and CEO to support facilities and community initiatives.
For investors and observers, following Tevogen news provides insight into how the company is advancing its precision T cell therapy programs, building out AI-driven target discovery, and managing its capital structure. Regular updates offer context on the company’s progress in infectious diseases, oncology, and neurology, as well as its stated focus on affordability and sustainable innovation.
Tevogen (Nasdaq: TVGN) is in advanced-stage evaluation to acquire a niche contract research organization operating in 20+ countries, targeting oncology, rare diseases, and medical devices. If completed, the deal is expected to add $20M+ in annual revenue and support double-digit growth beginning next year.
The company said the combination would expand global clinical capabilities and help build a scalable, cash-flow-oriented healthcare business; management also cited a potential path toward ~$100M in annual revenue pending additional transactions and execution.
Tevogen (Nasdaq: TVGN) announced it has regained compliance with the Nasdaq minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1) as of March 25, 2026. The Bid Price Requirement is a $1.00 per share closing threshold.
Tevogen previously received a notice on September 23, 2025 for failing to meet the $1.00 closing bid for 30 consecutive business days. With compliance restored, the company says it will continue pursuing a diversified healthcare strategy combining immunotherapy, artificial intelligence, and disciplined capital allocation, and will evaluate targeted acquisition opportunities while working toward a cash-flow-positive operating model.
Tevogen (Nasdaq: TVGN) announced that Mittul Mehta, Chief Information Officer and Head of Tevogen.AI, will speak at the Microsoft Fabric Community Conference (FabCon 2026) in Atlanta March 16–20, 2026. Mr. Mehta will appear in two sessions on March 18 and March 19 covering agentic AI, adaptive data pipelines, governance, and enterprise readiness.
The sessions tie to Tevogen.AI’s work applying advanced machine learning to biomedical discovery, including its published international patent application (WO 2025/129197).
Tevogen (Nasdaq: TVGN) reaffirmed capital discipline on March 13, 2026: the lead investor intends to maintain current holdings and the company does not expect to use more than 1% of authorized shares over the next 12 months or until cash-flow positive.
The company said only about 20% of shares are in the tradable float after excluding insider holdings, is prioritizing milestone‑linked stock incentives, is evaluating a one‑time special cash dividend contingent on financial milestones, and is assessing acquisitions that could add $50M+ combined annual revenue; Tevogen noted GAAP may not reflect full asset value and cited independent 2022 valuation above $4B.
Tevogen (Nasdaq: TVGN) reported advances in its Tevogen.AI PredicTcell™ beta, citing improved model metrics and expanded proprietary data and infrastructure on March 13, 2026.
The company reports a database of 655 million peptide sequences, training on 1.8 million data points, recall rising to 92%, and precision to 48%.
Tevogen (Nasdaq: TVGN) said it is advancing investigational T-cell therapy TVGN 489 toward a next clinical phase for Long COVID, timed to International Long COVID Awareness Month.
The company cited proof-of-concept data where treated high-risk patients did not develop Long COVID, expanded HLA coverage to ~65% of U.S. population, a new leadership team effective March 9, 2026, and continued evaluation of acquiring Sciometrix and its Clinicus platform to support real-world monitoring.
Tevogen (Nasdaq: TVGN) named interim leaders across five core verticals to execute an initial diversified growth strategy and announced potential acquisitions expected to operate as subsidiaries.
The company said the targeted transactions could collectively generate annual revenues exceeding $50 million and are expected to close by Q2 2026, subject to customary due diligence and definitive agreements.
Tevogen (Nasdaq: TVGN) CEO Dr. Ryan Saadi provided a shareholder letter (March 6, 2026) outlining strategic acquisition evaluations to complement its immunotherapy and AI platforms. The company said potential targets, if acquired as subsidiaries, may generate aggregate annual revenues in excess of $50 million, subject to due diligence and definitive agreements.
Tevogen emphasized disciplined capital allocation, operational efficiency, and a focus on building a sustainable, revenue-generating healthcare enterprise while pursuing these strategic initiatives.
Tevogen (Nasdaq: TVGN) signed a non-exclusive, non-binding Letter of Intent dated March 5, 2026 to evaluate a potential acquisition of Apozeal Pharmaceutical. The deal could provide Tevogen Generics with an established platform including 11 FDA-approved ANDA products, multiple ANDAs pending, and additional generics in development.
The transaction is subject to due diligence, negotiation of definitive agreements, regulatory approvals, and customary closing conditions, and there is no assurance the acquisition will be completed.
Tevogen (Nasdaq: TVGN) announced a 50-for-1 reverse stock split to regain compliance with Nasdaq's $1.00 minimum bid requirement. The split is expected to be effective at 12:01 a.m. on March 6, 2026, with shares trading on a split-adjusted basis under the same symbol and a new CUSIP.
No fractional shares will be issued; holders entitled to fractions will receive cash in lieu. Equity awards, warrants, incentive plan shares and preferred conversions will be proportionally adjusted. The company said the split will not affect underlying operations or total stockholders' equity.